Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Nasr Almusattar: What is the No-Reflow Phenomenon?
Nasr Almusattar/LinkedIn
May 3, 2026, 09:04

Nasr Almusattar: What is the No-Reflow Phenomenon?

Nasr Almusattar, Anesthesiologist Assistant, shared a post on LinkedIn:

“What is the No-Reflow Phenomenon?

The no-reflow phenomenon refers to the failure of microvascular perfusion despite successful restoration of blood flow in the major vessels.

In other words:

The artery is open, but blood does not reach the tissues at the capillary level.

It is a critical issue observed after Cardiopulmonary Bypass (CPB), affecting both the heart and the brain.

Pathophysiology (Why does it happen?)

  • No-reflow is mainly caused by microcirculatory dysfunction, due to:
  • Ischemia – Reperfusion Injury – Production of reactive oxygen species (ROS)
  • Endothelial Dysfunction – Reduced nitric oxide – vasoconstriction
  • Capillary Obstruction – Platelets, leukocytes, and microemboli block small vessels
  • Cellular Edema – Swelling compresses capillaries
  • Increased Blood Viscosity – Impairs microcirculatory flow

Cardiac No-Reflow

  • Occurs after restoring coronary circulation.
  • Clinical effects:
  • Poor myocardial contractility
  • Arrhythmias
  • Low cardiac output
  • Elevated lactate

Cerebral No-Reflow:

  • Occurs after restoration of cerebral perfusion.
  • Clinical effects:
  • Delayed awakening
  • Confusion or delirium
  • Neurological deficits

Diagnosis:

There is no single test, but clues include:

  1. Lactate levels
  2. Persistent organ dysfunction despite adequate flow
  3. Echocardiography (cardiac dysfunction)
  4. Cerebral oximetry (NIRS) if available

Management:

  • Management is supportive and multi-targeted

1. Optimize Hemodynamics

Maintain adequate MAP (65–80 mmHg)

Ensure sufficient cardiac output

2. Improve Microcirculation

Vasodilators (e.g., Nitroglycerin)

Reduce vasoconstriction

3. Reduce Blood Viscosity

Maintain optimal hematocrit (≈22–28%)

4. Prevent Microthrombosis

Adequate anticoagulation (Heparin during CPB)

5. Control Metabolic Factors

Normalize oxygenation, COâ‚‚, glucose, and electrolytes

6. Organ Support

  • Heart: Inotropes (e.g., Dobutamine)
  • Brain: Maintain cerebral perfusion pressure

Prevention (Most Important)

During CPB:

  • Minimize cross-clamp and bypass time
  • Use proper cardioplegia
  • Ensure effective de-airing (avoid microemboli)
  • Use filters in the circuit

Physiological Control:

  • Maintain adequate blood pressure and flow
  • Avoid extreme hemodilution
  • Control temperature (mild hypothermia)
  • Monitor electrolytes and glucose.”

Nasr Almusattar

Stay updated with Hemostasis Today.

CPB Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Nasr Almusattar
NewsFeed